BioNTech
NEWS
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.
It was another busy week in clinical trial news. Here’s a look.
A J&J spokesperson said yesterday that it is collecting more data on whether a booster shot is necessary.
As COVID-19 surges to earlier pandemic levels in the U.S., federal health officials are expected to authorize a third booster shot eight months after receiving the second of the Moderna and Pfizer-BioNTech vaccines, and probably the Johnson & Johnson vaccine as well.
The amended EUA is aimed at patients who have undergone solid organ transplants or those diagnosed with conditions that have an “equivalent level of immunocompromised.”
Citing a study from Johns Hopkins University, researchers found that immunocompromised people are 485 times more likely to end up in the hospital or die from COVID-19.
On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.
U.S. authorization is likely not a priority for Novavax since half the population is already vaccinated. But with other parts of the world, there’s still plenty of room for a Novavax vaccine.
JOBS
IN THE PRESS